As FDA Moves Away From Animal Testing, AI and Organoids Can Shine

Why It Matters

Eliminating animal tests accelerates R&D cycles, cuts costs, and aligns drug pipelines with more predictive human models, reshaping the biotech market landscape.

Key Takeaways

• FDA plans to phase out animal testing for certain drugs
• AI models accelerate target identification and safety predictions
• Organoids provide human-relevant efficacy data, reducing trial failures
• Regulatory roadmap guides industry transition to non‑animal methods
• Biotech firms investing heavily in digital and organoid platforms

Pulse Analysis

The FDA's decision to phase out animal testing marks a watershed moment for pharmaceutical regulation. Historically, pre‑clinical safety relied on rodent and canine studies, a process fraught with ethical concerns and limited translatability to humans. The FDA Modernization Act, currently moving through Congress, not only formalizes this shift but also provides a detailed roadmap outlining validation pathways for alternative methods. By setting clear expectations, the agency is encouraging companies to adopt scientifically advanced tools that can meet regulatory standards without relying on traditional vivisection.

Artificial intelligence and organoid technology are poised to fill the void left by animal models. Machine‑learning algorithms can analyze massive datasets to predict pharmacokinetics, toxicity, and off‑target effects far earlier than conventional screens. Meanwhile, organoids—three‑dimensional cultures derived from human stem cells—replicate organ‑specific physiology, offering a more accurate readout of drug efficacy and safety. Together, these platforms reduce the attrition rate in clinical trials, shorten development timelines, and lower overall R&D expenditures. Early adopters report faster go/no‑go decisions and more robust mechanistic insights, positioning AI‑driven and organoid‑based pipelines as competitive differentiators.

For biotech firms, the regulatory pivot translates into strategic investment opportunities. Venture capital is increasingly flowing into companies that specialize in AI drug design, high‑throughput organoid screening, and validation services that meet FDA guidelines. The upcoming National Biotechnology Conference in May will spotlight these innovations, signaling industry momentum. As the FDA’s non‑animal framework solidifies, firms that integrate these technologies will likely enjoy accelerated approvals, reduced compliance costs, and stronger market positioning, reshaping the competitive dynamics of drug development.

As FDA Moves Away From Animal Testing, AI and Organoids Can Shine

February 17 2026 · Jef Akst

Johns Hopkins’ Thomas Hartung discusses how drug discovery and development will change under evolving regulatory policies that embrace AI technology as well as organoid and other non‑animal models of human biology.

---

Last year, the FDA announced it would be phasing out animal‑testing requirements for some therapies. The NIH followed suit. According to Thomas Hartung, professor and chair at Johns Hopkins Bloomberg School of Public Health, these policy shifts are an “overdue adaptation to scientific progress.”

In this special edition of The Weekly, Hartung discusses how artificial intelligence (AI) and various non‑animal models such as human organoids will transform drug development and delivery, especially now that the regulatory side is catching up. The FDA Modernization Act, now making its way through Congress, codifies the FDA’s stated goal of starting to move away from animal testing. When the FDA made the announcement last year, it also released a roadmap for how to do this.

In May, Hartung will attend the National Biotechnology Conference in San Diego as a keynote speaker. BioSpace is a media partner of the meeting, and Managing Editor Jef Akst will also attend to moderate the executive track.

The 2026 National Biotechnology Conference runs May 11–14. You can find the agenda here.